504 related articles for article (PubMed ID: 25974833)
1. X-chromosome inactivation in female patients with Fabry disease.
Echevarria L; Benistan K; Toussaint A; Dubourg O; Hagege AA; Eladari D; Jabbour F; Beldjord C; De Mazancourt P; Germain DP
Clin Genet; 2016 Jan; 89(1):44-54. PubMed ID: 25974833
[TBL] [Abstract][Full Text] [Related]
2. X-inactivation in Fabry disease.
Elstein D; Schachamorov E; Beeri R; Altarescu G
Gene; 2012 Sep; 505(2):266-8. PubMed ID: 22710134
[TBL] [Abstract][Full Text] [Related]
3. X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay.
Rossanti R; Nozu K; Fukunaga A; Nagano C; Horinouchi T; Yamamura T; Sakakibara N; Minamikawa S; Ishiko S; Aoto Y; Okada E; Ninchoji T; Kato N; Maruyama S; Kono K; Nishi S; Iijima K; Fujii H
Clin Exp Nephrol; 2021 Nov; 25(11):1224-1230. PubMed ID: 34128148
[TBL] [Abstract][Full Text] [Related]
4. Female Fabry disease patients and X-chromosome inactivation.
Juchniewicz P; Kloska A; Tylki-Szymańska A; Jakóbkiewicz-Banecka J; Węgrzyn G; Moskot M; Gabig-Cimińska M; Piotrowska E
Gene; 2018 Jan; 641():259-264. PubMed ID: 29079200
[TBL] [Abstract][Full Text] [Related]
5. X-chromosomal inactivation patterns in women with Fabry disease.
Wagenhäuser L; Rickert V; Sommer C; Wanner C; Nordbeck P; Rost S; Üçeyler N
Mol Genet Genomic Med; 2022 Sep; 10(9):e2029. PubMed ID: 35971858
[TBL] [Abstract][Full Text] [Related]
6. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
[TBL] [Abstract][Full Text] [Related]
7. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.
Dobrovolny R; Dvorakova L; Ledvinova J; Magage S; Bultas J; Lubanda JC; Elleder M; Karetova D; Pavlikova M; Hrebicek M
J Mol Med (Berl); 2005 Aug; 83(8):647-54. PubMed ID: 15806320
[TBL] [Abstract][Full Text] [Related]
8. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis.
Viggiano E; Politano L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299283
[TBL] [Abstract][Full Text] [Related]
9. Pitfalls of X-chromosome inactivation testing in females with Fabry disease.
Řeboun M; Sikora J; Magner M; Wiederlechnerová H; Černá A; Poupětová H; Štorkánova G; Mušálková D; Dostálová G; Goláň L; Linhart A; Dvořáková L
Am J Med Genet A; 2022 Jul; 188(7):1979-1989. PubMed ID: 35338595
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation impact on Fabry disease.
Di Risi T; Vinciguerra R; Cuomo M; Della Monica R; Riccio E; Cocozza S; Imbriaco M; Duro G; Pisani A; Chiariotti L
Clin Epigenetics; 2021 Feb; 13(1):24. PubMed ID: 33531072
[TBL] [Abstract][Full Text] [Related]
11. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
12. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
[TBL] [Abstract][Full Text] [Related]
13. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
14. [Genetics of Fabry disease: diagnostic and therapeutic implications].
Germain DP
Presse Med; 2007 Mar; 36 Spec No 1():1S14-9. PubMed ID: 17546762
[TBL] [Abstract][Full Text] [Related]
15. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.
Whybra C; Kampmann C; Krummenauer F; Ries M; Mengel E; Miebach E; Baehner F; Kim K; Bajbouj M; Schwarting A; Gal A; Beck M
Clin Genet; 2004 Apr; 65(4):299-307. PubMed ID: 15025723
[TBL] [Abstract][Full Text] [Related]
16. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
17. Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.
Rodríguez Doyágüez P; Furlano M; Ars Criach E; Arce Y; Guirado L; Torra Balcells R
Nefrologia (Engl Ed); 2023 Dec; 43 Suppl 2():91-95. PubMed ID: 38278716
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
[TBL] [Abstract][Full Text] [Related]
19. Skewed X-chromosome inactivation plays a crucial role in the onset of symptoms in carriers of Becker muscular dystrophy.
Viggiano E; Picillo E; Ergoli M; Cirillo A; Del Gaudio S; Politano L
J Gene Med; 2017 Apr; 19(4):. PubMed ID: 28316128
[TBL] [Abstract][Full Text] [Related]
20. [Neurological complications of Fabry-disease].
Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]